# A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

> **NCT02064348** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 168 (actual)

## Conditions studied

- Diabetes
- Healthy

## Interventions

- **DRUG:** semaglutide
- **DRUG:** placebo
- **DRUG:** moxifloxacin

## Key facts

- **NCT ID:** NCT02064348
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-26
- **Primary completion:** 2015-04-23
- **Final completion:** 2015-04-23
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2018-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02064348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02064348, "A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02064348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*